/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
AbbVie (ABBV) has built a solid reputation among passive income-focused investors, backed by an impressive 54-year streak of dividend hikes. Much of that success has been fueled by Humira, a blockbuster drug that has generated enormous cash flows and helped fund the dividend payouts. So when Humira began losing exclusivity and biosimilar competition intensified, many investors feared that AbbVie’s dividend streak might come to an end.
However, AbbVie's recent first-quarter report shows that it can thrive well beyond Humira — while keeping its dividend strength firmly intact. Let's take a closer look.
